切割边缘的出血:小皮肤手术中抗凝药与抗血小板药继续使用的系统综述
该系统综述检索PubMed、MEDLINE、Embase和CENTRAL,纳入30项研究、超过14000例患者(其中超过5000例规律使用抗凝/抗血小板药),评估小皮肤手术中继续或停用抗凝/抗血小板药的血栓栓塞与出血并发症风险。血栓栓塞事件罕见但致残致死率高,3例事件与停药相关;阿司匹林单药治疗未见出血并发症增加,华法林和氯吡格雷单药证据矛盾且显示出血并发症率小幅增加;创口裂开、移植物失败、创口感染或美容效果未见增加。
要点
- 血栓栓塞事件罕见但致残致死率高,3例事件与停用抗凝/抗血小板药相关。
- 阿司匹林单药治疗未见出血并发症增加。
- 华法林和氯吡格雷单药证据矛盾,显示出血并发症率小幅增加。
核心结论
- 所有患者均需个体化风险评估,但临床医生应尽可能优先做到细致止血而非停用抗凝/抗血小板药。
研究设计与样本
- 系统综述,检索PubMed、MEDLINE、Embase和CENTRAL,纳入30项研究,数据来自超过14000例患者,其中超过5000例规律使用抗凝/抗血小板治疗。
主要发现
- 血栓栓塞事件罕见但致残致死率高,这些研究中3例事件与停用抗凝/抗血小板药相关。
- 阿司匹林单药治疗患者未见出血并发症增加。
- 华法林和氯吡格雷单药治疗证据矛盾,显示出血并发症率小幅增加。
- 创口裂开、移植物失败、创口感染或美容效果未见增加。
- 直接口服抗凝药(DOAC)研究过少,无法得出可靠结论;比较多种与单一抗凝/抗血小板方案的资料稀少。
临床怎么用
- 作者认为所有患者均需个体化风险评估,但临床医生应尽可能优先做到细致止血而非停用抗凝/抗血小板药。
局限性
- 直接口服抗凝药(DOAC)研究过少,无法得出可靠结论。
- 比较多种与单一抗凝/抗血小板方案的资料稀少。
- 使用皮肤移植或局部皮瓣的患者并发症率可能高于直接闭合,但证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticoagulant and antiplatelet (AC/AP) use is common and practice surrounding AC/AP continuation or cessation peri-operatively for minor cutaneous surgery lacks evidence-based consensus. OBJECTIVE: To determine the risks of haemorrhagic and thromboembolic complications associated with the continuation or cessation of AC/AP therapy in minor cutaneous surgery. METHODS: A systematic literature search was conducted using PubMed, MEDLINE, Embase and CENTRAL, to identify all articles involving the use of AC/AP in patients undergoing minor cutaneous surgery, including skin grafts and local flaps. Eligible studies were randomised control trials, prospective studies and retrospective studies in the English language. Studies investigating free-flap repairs, oculoplastic surgery and hand surgery were excluded. RESULTS: 30 studies included data from over 14,000 patients, of which more than 5000 took regular AC/AP therapy. Thromboembolic events were rare but carry high morbidity and even mortality, and in these studies three events were associated with cessation of AC/AP. There was no increase in haemorrhagic complications in patients taking aspirin monotherapy, but evidence is conflicting regarding warfarin and clopidogrel monotherapy, which shows a small increase in rate of bleeding complications. However, no increase in wound dehiscence, graft failure, wound infection or cosmetic outcome was seen. Too few studies investigated DOAC use to draw reliable conclusions. Data are sparse in comparing multiple versus single AC/AP regimens. Use of skin grafts or local flaps may have a greater complication rate than direct closure in patients on one or more AC/AP, but evidence is limited. CONCLUSION: A case-by-case risk assessment is warranted in all patients but where possible, clinicians should prioritise meticulous haemostasis over cessation of agents.
引用
- Isted A, Cooper L, Colville RJ, et al. Bleeding on the cutting edge: A systematic review of anticoagulant and antiplatelet continuation in minor cutaneous surgery. J Plast Reconstr Aesthet Surg. 2017. PMID: 29233507. doi:10.1016/j.bjps.2017.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。